BEYOND DOPAMINE BLOCKADE: MUSCARINIC RECEPTOR AGONISM AS A NOVEL THERAPEUTIC STRATEGY IN SCHIZOPHRENIA - A LITERATURE REVIEW OF XANOMELINE-TROSPIUM
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6521Keywords:
Xanomeline–trospium, Cobenfy, Schizophrenia, Muscarinic Receptor Agonist, Novel Antipsychotic, Treatment-resistant SchizophreniaAbstract
Background: Schizophrenia is a chronic mental illness affecting over 23 million people worldwide. Current pharmacotherapy, primarily based on dopamine D₂ receptor antagonism, is associated with significant adverse effects - including extrapyramidal symptoms, metabolic disturbances, and hyperprolactinemia - and up to 30% of patients show inadequate response.
Aim: This review aims to present and synthesize the available evidence on xanomeline–trospium (Cobenfy®) - the first approved antipsychotic with a predominantly muscarinic mechanism of action - as a novel therapeutic option for schizophrenia.
Methods: A narrative literature review was conducted in PubMed, Scopus, Web of Science, and Google Scholar databases up to June 2026, focusing on peer‑reviewed articles, clinical trials, and systematic reviews on xanomeline–trospium in schizophrenia.
Results: Xanomeline–trospium demonstrated significant antipsychotic efficacy across the Phase 2 and Phase 3 EMERGENT trials, with moderate‑to‑large effect sizes (Cohen's d = 0.60). The safety profile is distinctly favorable: no extrapyramidal symptoms, weight gain, metabolic disturbances, or prolactin elevation were observed. Gastrointestinal adverse events (nausea, vomiting, constipation) were the most common but were generally mild, transient, and occurred early in treatment. Long‑term open‑label extension studies confirmed sustained efficacy and safety over 52 weeks, with ecological momentary assessment data indicating improvements in real‑world social functioning and positive affect.
Conclusions: Xanomeline–trospium represents a promising alternative for schizophrenia treatment, particularly for patients intolerant to conventional antipsychotics or those with metabolic comorbidities. Its novel mechanism and favorable tolerability profile position it as a significant advancement in psychopharmacology. Further research is needed to clarify its role in treatment‑resistant schizophrenia and to confirm long‑term outcomes in diverse populations.
References
Brannan, S. K., Sawchak, S., Miller, A. C., Lieberman, J. A., Paul, S. M., & Breier, A. (2021). Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. The New England Journal of Medicine, 384(8), 717–726. https://doi.org/10.1056/NEJMoa2017015
Bristol-Myers Squibb Company. (2024). Cobenfy: Highlights of prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216158s000lbl.pdf
Colosimo, C., Jain, R., Duma, K., Kurzeja, A., & Arango, C. (2026). A European perspective on tardive dyskinesia. European Neuropsychopharmacology, 104, 112740. https://doi.org/10.1016/j.euroneuro.2025.11.017
Correll, C. U., Angelov, A. S., Miller, A. C., Weiden, P. J., & Brannan, S. K. (2022). Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. Schizophrenia, 8(1), 109. https://doi.org/10.1038/s41537-022-00320-1
Correll, C. U., & Howes, O. D. (2021). Treatment-Resistant Schizophrenia: Definition, Predictors, and Therapy Options. The Journal of Clinical Psychiatry, 82(5). https://doi.org/10.4088/JCP.MY20096AH1C
Correll, C. U., Solmi, M., Croatto, G., Schneider, L. K., Rohani-Montez, S. C., Fairley, L., Smith, N., Bitter, I., Gorwood, P., Taipale, H., & Tiihonen, J. (2022). Mortality in people with schizophrenia: A systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry: Official Journal of the World Psychiatric Association, 21(2), 248–271. https://doi.org/10.1002/wps.20994
Crawford, P., & Go, K. V. (2022). Schizophrenia. American Family Physician, 106(4), 388–396.
Falkai, P., Wagner, E., John, M., Yakimov, V., Galderisi, S., Bitter, I., Dom, G., Schmitt, A., Gaebel, W., Carpiniello, B., & Hasan, A. (2025). Developing the EPA guidance of pharmacological treatment of schizophrenia—Results of a Delphi process. European Psychiatry: The Journal of the Association of European Psychiatrists, 68(1), e26. https://doi.org/10.1192/j.eurpsy.2024.1794
GDB 2021 Schizophrenia Collaborators. (2026). The Global Burden of Schizophrenia: Findings from the 2021 Global Burden of Diseases, Injuries, and Risk Factors Study. Schizophrenia Bulletin Open, 7(1), sgag012. https://doi.org/10.1093/schizbullopen/sgag012
Harvey, P. D., Kaul, I., Chataverdi, S., Patel, T., Claxton, A., Sauder, C., Saber, J. N., Brannan, S. K., & Horan, W. P. (2025). Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophrenia. Schizophrenia Research, 276, 117–126. https://doi.org/10.1016/j.schres.2025.01.019
Howes, O. D., Thase, M. E., & Pillinger, T. (2022). Treatment resistance in psychiatry: State of the art and new directions. Molecular Psychiatry, 27(1), 58–72. https://doi.org/10.1038/s41380-021-01200-3
Kaul, I., Claxton, A., Chaturvedi, S., Patel, T., Wu, H., Sawchak, S., & Sauder, C. (2026). Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5). Schizophrenia Research, 288, 86–94. https://doi.org/10.1016/j.schres.2025.12.015
Kaul, I., Claxton, A., Sauder, C., Patel, T., Chaturvedi, S., Brown, D., Zhu, H., Marcus, R., Sawchak, S., & Brannan, S. K. (2026). Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial. The American Journal of Psychiatry, 183(3), 183–192. https://doi.org/10.1176/appi.ajp.20241186
Kaul, I., Claxton, A., Sawchak, S., Sauder, C., Brannan, S. K., Raj, E., Ruan, S., Konis, G., Brown, D., Cutler, A. J., & Marcus, R. (2025). Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials. The Journal of Clinical Psychiatry, 86(1). https://doi.org/10.4088/JCP.24m15497
Kaul, I., Sawchak, S., Walling, D. P., Tamminga, C. A., Breier, A., Zhu, H., Miller, A. C., Paul, S. M., & Brannan, S. K. (2024). Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry, 81(8), 749–756. https://doi.org/10.1001/jamapsychiatry.2024.0785
Leucht, S., Priller, J., & Davis, J. M. (2024). Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application. American Journal of Psychiatry, 181(10), 865–878. https://doi.org/10.1176/appi.ajp.20240738
Lin, X., Siafis, S., Tian, J., Wu, H., Qin, M., Correll, C. U., Schneider-Thoma, J., & Leucht, S. (2025). Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis. CNS Drugs, 39(10), 937–947. https://doi.org/10.1007/s40263-025-01218-z
Mazur, M., Żak, K., Michalak, K., Zukierski, K., Jarych, W., Pliszka, A., Jucha, H., Madyniak, K., & Kluz, A. (2025). Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment—Review. Quality in Sport, 40, 59815. https://doi.org/10.12775/QS.2025.40.59815
Meyer, J. M., Kramer, K., Vuocolo, S., Kaul, I., & Miller, A. C. (2025). From theory to therapy: Unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials. International Journal of Neuropsychopharmacology, 28(4), pyaf015. https://doi.org/10.1093/ijnp/pyaf015
Morrison, P. D., Jauhar, S., & Young, A. H. (2025). The mechanism of action of clozapine. Journal of Psychopharmacology, 39(4), 297–300. https://doi.org/10.1177/02698811251319458
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016). Schizophrenia. Lancet, 388(10039), 86–97. https://doi.org/10.1016/S0140-6736(15)01121-6
Paul, S. M., Yohn, S. E., Popiolek, M., Miller, A. C., & Felder, C. C. (2022). Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia. American Journal of Psychiatry, 179(9), 611–627. https://doi.org/10.1176/appi.ajp.21101083
Ramey, O. L., & Silva Almodóvar, A. (2025). Xanomeline-Trospium: A Novel Therapeutic for the Treatment of Schizophrenia. The Annals of Pharmacotherapy, 59(10), 937–950. https://doi.org/10.1177/10600280251324642
Siafis, S., Wu, H., Wang, D., Burschinski, A., Nomura, N., Takeuchi, H., Schneider-Thoma, J., Davis, J. M., & Leucht, S. (2023). Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: A systematic review and dose-response meta-analysis. Molecular Psychiatry, 28(8), 3267–3277. https://doi.org/10.1038/s41380-023-02203-y
Smith, C. M., Augustine, M. S., Dorrough, J., Szabo, S. T., Shadaram, S., Hoffman, E. O. G., & Muzyk, A. (2025). Xanomeline-trospium (CobenfyTM) for Schizophrenia: A Review of the Literature. Clinical Psychopharmacology and Neuroscience: The Official Scientific Journal of the Korean College of Neuropsychopharmacology, 23(1), 2–14. https://doi.org/10.9758/cpn.24.1253
Solmi, M., Seitidis, G., Mavridis, D., Correll, C. U., Dragioti, E., Guimond, S., Tuominen, L., Dargél, A., Carvalho, A. F., Fornaro, M., Maes, M., Monaco, F., Song, M., Il Shin, J., & Cortese, S. (2023). Incidence, prevalence, and global burden of schizophrenia—Data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Molecular Psychiatry, 28(12), 5319–5327. https://doi.org/10.1038/s41380-023-02138-4
Striebel, J. M. (2024). What is schizophrenia—Symptomatology. CNS Spectrums, 30(1), e12. https://doi.org/10.1017/S1092852924000622
Targum, S. D., Watson, C., Claxton, A., Nicolas, P., Novak, K. D., Kaul, I., Marder, S. R., Lin, W.-C., Horan, W. P., Marcus, R., & Brannan, S. K. (2026). Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia. Schizophrenia Research, 292, 53–59. https://doi.org/10.1016/j.schres.2026.03.004
Verma, S., Kumar, A., Tripathi, T., & Kumar, A. (2018). Muscarinic and nicotinic acetylcholine receptor agonists: Current scenario in Alzheimer’s disease therapy. The Journal of Pharmacy and Pharmacology, 70(8), 985–993. https://doi.org/10.1111/jphp.12919
Ying, J., Chew, Q. H., McIntyre, R. S., & Sim, K. (2023). Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review. Genes, 14(3), 689. https://doi.org/10.3390/genes14030689
Yohn, S. E., Harvey, P. D., Brannan, S. K., & Horan, W. P. (2024). The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia. Frontiers in Psychiatry, 15, 1421554. https://doi.org/10.3389/fpsyt.2024.1421554
Żełabowski, K., Pichowicz, W., Dembowska, J., Szwajkowski, M., Mykhailova, D., Wurm, G., Biedka, K., Błaszczyk, K., & Piotrowski, P. (2026). From dopamine to muscarine: Xanomeline-trospium (KarXT) as a novel direction in the psychopharmacotherapy of schizophrenia. Frontiers in Pharmacology, 17, 1774437. https://doi.org/10.3389/fphar.2026.1774437
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Przemysław Dominik Drabik, Diana Morawska, Aleksandra Katarzyna Pelczar, Wiktoria Oczkowska, Alex Malinowski, Klaudia Marchewka, Radosław Sochocki, Wiktoria Białek, Agata Sadowska, Emilia Piaszczyńska, Monika Waszak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
